RPAM
MBX

Rhenman & Partners Asset Management’s MBX Biosciences MBX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Buy
+62,000
New +$2.17M 0.32% 83

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Rhenman & Partners Asset Management's MBX Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in MBX Biosciences (MBX) in Q2 2026: 62,000 shares worth $3.42M. The stake represents 0.32% of the portfolio and ranks #83 among its holdings.

173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Rhenman & Partners Asset Management held 62,000 shares of MBX Biosciences worth $3.42M as of Q2 2026.
  • MBX Biosciences was a new Rhenman & Partners Asset Management position in Q2 2026.
  • MBX Biosciences made up 0.32% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #83 holding.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.